Biocon Biologics 通过 $1.1M 债券发行和银团贷款为 $800B 债务再融资，以实现长期增长。 Biocon Biologics refinances $1.1B debt through $800M bond issuance and syndicated facility for long-term growth.
Biocon Biologics 通过发行 8 亿美元的新债券和银团贷款，为 11 亿美元的长期债务进行了再融资。 Biocon Biologics has refinanced $1.1 billion in long-term debt through a new $800 million bond issuance and a syndicated facility. 此举旨在加强财政灵活性,支持长期增长,允许对生物相似的管道进行再投资。 This move aims to enhance financial flexibility and support long-term growth, allowing for reinvestment in its biosimilar pipeline. 这些债券定于2029年到期,利率为6.67%的优惠券,被S&P和Fitch评级为BB,并将在新加坡证券交易所上市。 The bonds, set to mature in 2029 with a 6.67% coupon, are rated BB by S&P and Fitch and will be listed on the Singapore Stock Exchange. 预计交易将于2024年10月9日结束。 The transaction is expected to close on October 9, 2024.